LINCOLN — LINCOLN PHARMACEUTICALS Share Price
0.000.00%
Last trade - 00:00- IN₹11.88bn
- IN₹9.89bn
- IN₹5.81bn
- 97
- 32
- 64
- 74
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.72 | ||
| PEG Ratio (f) | 0.64 | ||
| EPS Growth (f) | 17.76% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.86 | ||
| Price to Tang. Book | 1.86 | ||
| Price to Free Cashflow | 46.98 | ||
| Price to Sales | 1.99 | ||
| EV to EBITDA | 10.62 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.25% | ||
| Return on Equity | 15.08% | ||
| Operating Margin | 13.52% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 3,864.91 | 4,241.85 | 4,721.23 | 5,103.09 | 5,805.5 | 6,440 | 7,480 | 9.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +5.36 | +21 | +11.21 | +5.23 | +27.69 | +11.18 | +17.76 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lincoln Pharmaceuticals Limited is engaged in the business of manufacturing and trading of pharmaceutical products like medicines, injections and other related products. The Company’s product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, liquid injection, and pharma products. It offers products for anti-infective, respiratory system, gynecology, cardio and CNS (central nervous system), antibacterial, anti-diabetic, and anti-malaria. The Company serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia, and 26 states across India. The Company's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms), and Tinnex Capsule used to treat tinnitus.
Directors
- Kishor Shah NEC (69)
- Munjal Patel FID
- Niren Desai CCO
- Arvindbhai Patel CCO (64)
- Mahendrabhai Patel MDR
- Rajnikant Patel MDR
- Hasmukhbhai Patel EDR
- Ashish Patel DRC
- Meha Patel IND
- Saurin Parikh NID (47)
- Ishwarlal Patel NID (78)
- Pirabhai Suthar NID (67)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 20th, 1995
- Public Since
- February 8th, 1996
- No. of Shareholders
- 31,973
- No. of Employees
- 1,700
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 20,029,700
- Address
- LINCOLN HOUSE, B/h. Satyam Complex, AHMEDABAD, 380060
- Web
- https://www.lincolnpharma.com/
- Phone
- +91 7967778000
- Auditors
- J.T. Shah & Co.
Upcoming Events for LINCOLN
Q1 2026 Lincoln Pharmaceuticals Ltd Earnings Release
Similar to LINCOLN
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the LINCOLN PHARMACEUTICALS share price?
As of Today at 03:45 UTC, shares in LINCOLN PHARMACEUTICALS are trading at IN₹593.20. This share price information is delayed by 15 minutes.
How has the LINCOLN PHARMACEUTICALS share price performed this year?
Shares in LINCOLN PHARMACEUTICALS last closed at IN₹593.20 and the price had moved by -1.19% over the past 365 days. In terms of relative price strength the LINCOLN PHARMACEUTICALS share price has underperformed the S&P BSE 100 Index by -6.92% over the past year.
What are the analyst and broker recommendations for LINCOLN PHARMACEUTICALS?
The overall consensus recommendation for LINCOLN PHARMACEUTICALS is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the LINCOLN PHARMACEUTICALS dividend yield?
The LINCOLN PHARMACEUTICALS dividend yield is 0.3% based on the trailing twelve month period.
Does LINCOLN PHARMACEUTICALS pay a dividend?
Last year, LINCOLN PHARMACEUTICALS paid a total dividend of IN₹1.80, and it currently has a trailing dividend yield of 0.3%. We do not have any data on when LINCOLN PHARMACEUTICALS is to next pay dividends.
When does LINCOLN PHARMACEUTICALS next pay dividends?
We do not have data on when LINCOLN PHARMACEUTICALS is to next pay dividends. The historic dividend yield on LINCOLN PHARMACEUTICALS shares is currently 0.3%.
How do I buy LINCOLN PHARMACEUTICALS shares?
To buy shares in LINCOLN PHARMACEUTICALS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of LINCOLN PHARMACEUTICALS?
As of the previous close price of IN₹593.20, shares in LINCOLN PHARMACEUTICALS had a market capitalisation of IN₹11.88bn.
Where are LINCOLN PHARMACEUTICALS shares listed?
Here are the trading details for LINCOLN PHARMACEUTICALS:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: LINCOLN
What kind of share is LINCOLN PHARMACEUTICALS?
Based on an overall assessment of its quality, value and momentum LINCOLN PHARMACEUTICALS is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a LINCOLN PHARMACEUTICALS share price forecast for 2025?
The analyst consensus target price for shares in LINCOLN PHARMACEUTICALS is IN₹1,008.00. That is 69.93% above the last closing price of IN₹593.20.
Analysts covering LINCOLN PHARMACEUTICALS currently have a consensus Earnings Per Share (EPS) forecast of IN₹51.80 for the next financial year.
Find out moreWhat is the trend in the LINCOLN PHARMACEUTICALS share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LINCOLN PHARMACEUTICALS. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -6.55%.
As of the last closing price of IN₹593.20, shares in LINCOLN PHARMACEUTICALS were trading -12.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the LINCOLN PHARMACEUTICALS PE Ratio?
The LINCOLN PHARMACEUTICALS PE ratio based on its reported earnings over the past 12 months is 9.72. The shares last closed at IN₹593.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of LINCOLN PHARMACEUTICALS?
LINCOLN PHARMACEUTICALS' management team is headed by:
- Kishor Shah - NEC
- Munjal Patel - FID
- Niren Desai - CCO
- Arvindbhai Patel - CCO
- Mahendrabhai Patel - MDR
- Rajnikant Patel - MDR
- Hasmukhbhai Patel - EDR
- Ashish Patel - DRC
- Meha Patel - IND
- Saurin Parikh - NID
- Ishwarlal Patel - NID
- Pirabhai Suthar - NID